#None #Milan #Biosimilars #Kexing Biopharm #CPHI Milan

Kexing Biopharm Exhibits at CPHI Milan 2026

From October 6 to 8, 2026, Kexing Biopharm (688136.SH) made a significant impression at the CPHI Milan 2026 trade show, showcasing its extensive and innovative drug portfolio to an international audience. The event served as a pivotal platform for Kexing Biopharm to connect with various stakeholders including pharmaceutical buyers, biotechnology firms, and industry partners from around the globe.

In recent years, Kexing Biopharm has successfully established a robust international commercialization platform, forming over 30 overseas collaborations with various national pharmaceutical laboratories. These collaborations span several therapeutic areas, such as oncology, autoimmune diseases, and metabolic disorders. The company’s marketing network now reaches approximately 70 countries and regions, reflecting its commitment to expanding its global footprint.

Kexing's flagship product, albumin-bound paclitaxel, has seen significant success in Europe, where it is already approved for sale in the EU, UK, and other regions. The company is also actively developing more than 10 high-value biosimilars aimed at global markets, targeting unmet clinical needs while capitalizing on market potential.

To further strengthen its local presence in Europe, Kexing Biopharm has established a subsidiary in Germany and is pursuing additional branches in countries like France, Spain, Italy, the UK, and the Netherlands. These local endeavors will enable Kexing to meet the diverse needs of its regional clients more efficiently and foster long-term relationships with industry partners. Participation in CPHI events over the past years has played a critical role in enhancing Kexing’s visibility within the European market and facilitating direct communication with local stakeholders.

Kexing Biopharm's central strategic theme of "Innovation + Internationalization" was prominently featured at the expo. Visitors were particularly interested in innovative drug research projects focused on areas such as cancer cachexia, ophthalmic therapies, systemic lupus erythematosus, and chronic inflammatory bowel diseases. These projects specifically cater to chronic disease markets and address significant clinical unmet needs.

The quality of products remains fundamental for successful international expansion. With over 30 years of industrial experience in the biopharmaceutical sector, Kexing Biopharm has implemented reliable manufacturing systems and quality management protocols. The company's albumin-bound paclitaxel production chain has received EU GMP certification, and the product is authorized in over 40 countries and regions.

Looking ahead, Kexing Biopharm is committed to continuing its journey of innovation and high-quality drug commercialization. By working alongside global partners, the company aims to make significant contributions to improving the health of populations worldwide. Through strategic collaborations and the enhancement of their product portfolio, Kexing Biopharm is set to lead the charge in addressing healthcare needs on a global scale.